Research programme: haemostasis therapy - Haemostatix

Drug Profile

Research programme: haemostasis therapy - Haemostatix

Alternative Names: HaemoPlax; HXTC-901; Systemic haemostat - Haemostatix

Latest Information Update: 15 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Haemostatix
  • Class Albumins; Peptides
  • Mechanism of Action Fibrin stimulants; Fibrinogen modulators; Platelet aggregation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Surgical blood loss; Thrombocytopenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in United Kingdom (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for research development in Surgical-blood-loss(Prevention) in United Kingdom (IV, Infusion)
  • 06 Aug 2014 Early research in prevention of Surgical blood loss is ongoing in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top